Status:
COMPLETED
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
Lead Sponsor:
Centre Hospitalier Universitaire Vaudois
Collaborating Sponsors:
Ludwig Institute for Cancer Research
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and to assess the sa...
Detailed Description
Immune therapy with tumor antigenic peptides is generally quite well tolerated. However, immune activation is often only weak or even undetectable, and clinical responses (supposedly corresponding to ...
Eligibility Criteria
Inclusion
- Histologically confirmed stage III or stage IV melanoma
- Tumor expression of Melan-A +/- Tyrosinase
- Human leukocyte antigen-A2 (HLA-A2) positive
Exclusion
- Clinically significant heart disease
- Serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders or uncontrolled peptic ulcer, or seizure or central nervous system disorders
- History of immunodeficiency disease or autoimmune disease
- Coagulation or bleeding disorders
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00112229
Start Date
April 1 2003
End Date
June 1 2012
Last Update
April 22 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ludwig Institute for Cancer Research + Multidisciplinary Oncology Center at the Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland, 1011